Cargando…
Recombinant transforming growth factor beta 1 and beta 2 protect mice from acutely lethal doses of 5-fluorouracil and doxorubicin
Transforming growth factor beta 1 (TGF-beta 1) and TGF-beta 2 can reversibly inhibit the proliferation of hematopoietic progenitor cells in vivo, leading us to hypothesize that such quiescent progenitors might be more resistant to high doses of cell cycle active chemotherapeutic drugs, thereby allow...
Formato: | Texto |
---|---|
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
1994
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2191629/ https://www.ncbi.nlm.nih.gov/pubmed/8064224 |
Ejemplares similares
-
Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin
Publicado: (1990) -
A phase II study of recombinant interferon-beta (r-hIFN-beta 1a) in combination with 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma.
por: Joffe, J. K., et al.
Publicado: (1997) -
Expression of transforming growth factors beta-1, beta 2 and beta 3 in human bladder carcinomas.
por: Eder, I. E., et al.
Publicado: (1997) -
Straightening Beta: Overdispersion of Lethal Chromosome Aberrations following Radiotherapeutic Doses Leads to Terminal Linearity in the Alpha–Beta Model
por: Shuryak, Igor, et al.
Publicado: (2017) -
Transforming growth factors-beta 1 and beta 2 are mitogens for rat Schwann cells
Publicado: (1989)